Frontiers is at the forefront of building this ultimate Open Science platform. By taking publishing entirely online, we drive innovations and develop new technologies to make peer-review more efficient and transparent, provide impact metrics for articles and researchers, are the first – and only – to merge open-access publishing with a research network platform, Loop, to catalyse collaboration and research dissemination and we popularize research to the public, including kids. Our mission is to increase the reach and impact of articles and their authors.
Frontiers today publishes several of the most cited Open-access journals in the world, is today one of the largest and fastest-growing open-access publishers, receives millions of monthly page views, received the ALPSP Gold Award for Innovation in Publishing in 2014, has publishing agreements with many universities, and collaborates with Nature Publishing Group, Scientific American, Digital Science, OpenAire, CrossRef, OASPA, COPE, Jacobs Foundation, and others to advance Open Science worldwide.
JOURNAL IMPACT
Our 2017 analysis of journal impact shows Frontiers journals lead in citations in their fields and rank in the top Impact Factor Percentiles. The results are based on the 2016 Journal Citation Reports (JCR), released in 2017 by Clarivate Analytics (f.k.a. Thomson Reuters), for citations in 2016 of articles published in 2014-2015. Frontiers journals are listed across 20 academic categories in the 2016-JCR. Read the full analysis here.
Notably, Frontiers reached 6.4 on Journal Impact Factors and are consistently ranked among the best performing journals. Compared to all journals (subscription and open-access) Frontiers journals rank 1st most cited in 4 categories, namely Neurosciences, Psychology, Multidisciplinary Psychology, and Plant Sciences. Our journals also rank 2nd most cited in the category of Physiology, 3rd most cited in Microbiology and 5th most cited in Immunology.
Compared to just open-access journals, Frontiers journals are the 1st most cited in 6 categories (Neurosciences, Psychology, Multidisciplinary Psychology, Plant Sciences, Pharmacology & Pharmacy, and Immunology) and are 2nd most cited in 3 categories (Clinical Neurology, Endocrinology, and Microbiology).
- Forums
- ASX - By Stock
- NTI
- Ann: Clinical Trial Publication Provisionally Accepted
Ann: Clinical Trial Publication Provisionally Accepted, page-45
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.9¢ |
Change
0.002(2.99%) |
Mkt cap ! $64.55M |
Open | High | Low | Value | Volume |
6.7¢ | 7.2¢ | 6.7¢ | $45.29K | 648.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 684701 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.9¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 589299 | 0.070 |
1 | 36231 | 0.069 |
5 | 240000 | 0.068 |
2 | 255000 | 0.067 |
3 | 262000 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 100000 | 1 |
0.074 | 40000 | 1 |
0.075 | 738582 | 2 |
0.076 | 90000 | 1 |
0.077 | 190000 | 3 |
Last trade - 15.37pm 22/11/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online